This paper examines the marketing and pricing crisis facing Sigma Pharmaceuticals Ltd., an Australian pharmaceutical company, in early 2010. Drawing on reporting from the Australian Financial Review and related sources, the analysis identifies two core problems: a damaged market position stemming from preferential treatment given to large pharmacy chains, and pricing policies that generated cash-flow instability and regulatory scrutiny. The paper argues that Sigma must reposition its corporate image toward smaller, independent pharmacies while reforming its credit and discount structures. Without comprehensive marketing intervention, the company risks losing its standing as a market leader.
Sigma Pharmaceuticals Ltd. is an Australian company, founded in 1912, that produces over-the-counter drugs and prescription medications. It employs just under 2,000 people and posted 2008 revenues of $2.6 billion (AUD). Recent developments, however, have been far less encouraging. At the end of February 2010, Sigma shares were placed on hold following a profit warning. Since then, the company has been under investigation for accounting irregularities, price-fixing, and preferential treatment and pricing extended to certain pharmacy chains. The general view is that Sigma was engaging in price-fixing that favored its own chains — Amcal and Guardian — as well as other large chains, at the expense of smaller, independent pharmacies (Collins, 2010).
An article in the Australian Financial Review concerning Sigma Pharmaceuticals focuses on two core issues: (a) positioning and (b) price considerations. Sigma faces a series of major marketing and pricing problems that threaten to severely impact its cash flow, undermine its ability to compete fairly, and erode public confidence.
Sigma recognizes that it must quickly change its image with smaller, non-chain pharmacies in order to regain their business and shift public perception. The company needs to reposition its image — not necessarily its product lines. The central issue is that Sigma has been giving preferential treatment to its own chains and large pharmacy and drug-store chains, including larger credit lines, deeper discounts, and more favorable terms. The objective of market positioning is to identify the appropriate niche for the company and use every available means to promote that position. In this case, most analysts agree that Sigma needs to adopt a more family-friendly, less top-heavy, "we care" corporate image in order to rebuild trust with smaller operators and the general public.
"Extended credit terms cause financial instability"
"Government investigation and trading suspension details"
Mercer, K. (April 8, 2010). "Sigma Ready to Revise Trading Terms." The Australian Financial Review. Retrieved from www.afr.com
Symons, D. (March 4, 2010). "Terms of Trade." The Sydney Morning Herald. Retrieved from http://www.smh.com.au/business/picture-looks-bleak-for-telstra-20100303-piza.html
You’re 42% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.